Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers

Journal of Clinical Pharmacology

Volumn 37, Issue 8, 1997, Pages 737-743

  Hsyu, Poe Hirr ^a   Singh, Ashish ^a   Giargiari, Tracie D ^a   Dunn, John A ^a   Ascher, John A ^a   Johnston, J Andrew ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; HUMAN; METABOLITE; ORAL DRUG ADMINISTRATION; SMOKING; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION;

EID: 0030768505     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04361.x     Document Type: Article

References (17)

1. Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, Harto NE: A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51:194-199.
2. Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52:329-335.
3. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM: Evidence that the acute behavioral and electrophysiological effects of bupropion (WELLBUTRIN®) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994;11:133-141.
4. Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, et al: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
5. Schroeder DH: Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81.
6. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA: Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38:586-589.
7. Commins BT, Cooper RL, Lindsey AJ: Polycyclic hydrocarbons in cigarette smoke. Cancer 1954;8:269-302.
8. Schein JR: Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995;29:1139-1148.
9. DeVane CL, Laizzure SC, Stewart JT, Kolts BE, Ryerson EG, Miller RL, et al: Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990;10:328-332.
10. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, et al: Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21:127-135.
11. Lai AA, Schroeder DH: Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983;44:82-84.
12. Jusko WJ: Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 1979;9:221-236.
13. Miller L: Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989;17:90-108.
14. Patel DK, Wurm R, Dunn J, Silver I: In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450s. ISXX Proceedings 1996;10:371.
15. Jacob P III, Benowitz NL: Oxidative metabolism of nicotine in vivo. In, Adlkofer F, Thuraus K (eds.): Effects of Nicotine on Biological Systems. Basel: Birkhauser-Verlag, 1991;35-44.
16. Flammang AM, Gelboin HV, Aoyama T, Gonzalez FJ, McCoy GD: Nicotine metabolism by cDNA-expressed human cytochrome P-450S. Biochem Arch 1992;8:1-8.
17. Goodnick PJ: Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 1991;27:513-519.